GlassScriptPhysician profile
Melissa Ianitelli
NPI 1497066963
$10,784.60
in general payments reported to CMS, 2019-2025
34 companies · $747 in 2025
The $747 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,771 · 2020: $675 · 2021: $1,259 · 2022: $1,010 · 2023: $2,646 · 2024: $1,676 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,069.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,068.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,355.45 | 2019-2025 | Aveir, Pressurewire, Xience Skypoint |
| Boston Scientific Corporation | $1,839.12 | 2019-2025 | Watchman Access System, Watchman Flx, Ranger |
| Janssen Pharmaceuticals, INC | $558.57 | 2019-2024 | Xarelto |
| Edwards Lifesciences Corporation | $539.66 | 2019-2022 | |
| Angiodynamics, INC. | $505.06 | 2023-2024 | Alphavac, Angiovac |
| E.R. Squibb & Sons, L.L.C. | $503.08 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $494.34 | 2019-2024 | |
| Inari Medical, INC. | $438.22 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $426.08 | 2019-2025 | Lifevest |
| Pfizer INC. | $400.50 | 2021-2024 | |
| Kestra Medical Technology Services, INC. | $367.28 | 2023-2024 | Assure Wcd |
| Cardiovascular Systems INC. | $292.04 | 2020-2021 | |
| Amgen INC. | $281.95 | 2019-2024 | Repatha |
| Bracco Diagnostics INC. | $260.74 | 2019 | |
| Astellas Pharma US INC | $216.77 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $194.45 | 2021-2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.30 | 2022-2024 | Jardiance |
| Abiomed | $161.35 | 2020-2025 | |
| Philips North America LLC | $154.12 | 2022-2025 | Encore |
| Bayer Healthcare Pharmaceuticals INC. | $128.45 | 2019 | |
| Ekos Corporation | $105.65 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $97.08 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $58.89 | 2019-2022 | |
| Scpharmaceuticals INC. | $34.64 | 2023 | |
| Daiichi Sankyo INC. | $34.55 | 2022-2023 | Injectafer |
| Irhythm Technologies, INC. | $31.21 | 2023 | Zio Xt Patch |
| Regeneron Healthcare Solutions, INC. | $27.23 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $23.04 | 2023 | Uptravi, Opsumit |
| Zoll Circulation INC | $20.00 | 2022 | |
| United Therapeutics Corporation | $18.66 | 2019 | |
| Merck Sharp & Dohme LLC | $17.44 | 2024 | Verquvo |
| Baxter Healthcare | $14.97 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Gilead Sciences, INC. | $12.71 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Ianitelli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.